Chemotherapy agents alter plasma lipids in breast cancer patients and show differential effects on lipid metabolism genes in liver cells

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Sharma, Monika ^a   Tuaine, Jo ^b   McLaren, Blair ^b   Waters, Debra L ^a   Black, Katherine ^a   Jones, Lynnette M ^a   McCormick, Sally P A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DUNEDIN HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; APOA1 PROTEIN, HUMAN; LIPID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CELL VIABILITY; CLINICAL ARTICLE; CORRELATIONAL STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; PROTEIN EXPRESSION; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CHOLESTEROL, HDL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; LIPIDS; LIVER; MIDDLE AGED; PPAR GAMMA;

EID: 84958190871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148049     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011; 61: 69-90.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365: 1687-717.
3. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-Term cancer survivors. Int J Cancer J Int Cancer. 2003; 104: 488-95.
4. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004; 91: 37-44.
5. Shenoy C, Klem I, Crowley AL, Patel MR, Winchester MA, Owusu C, et al. Cardiovascular Complications of Breast Cancer Therapy in Older Adults. The Oncologist. 2011; 16: 1138-43. doi: 10.1634/theoncologist.2010-0348
6. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. 2011; 13: R64. doi: 10.1186/bcr2901
7. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28. J Clin Oncol. 2005; 23: 3686-96.
8. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52: 1213-25. doi: 10.1016/j.yjmcc.2012.03.006
9. Steinherz LJ, Steinherz PG, Mangiacasale D, O'Reilly R, Allen J, Sorell M, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol. 1981; 9: 417-22.
10. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol Off J Am Soc Clin Oncol. 1995; 13: 2688-99.
11. Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience. Int J Cancer J Int Cancer. 2001; 93: 139-41.
12. Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A, Raptis S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol. 1992; 30: 412-6.
13. Rzymowska J. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients. Pathobiol J Immunopathol Mol Cell Biol. 1999; 67: 129-32.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
15. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995; 41: 246-55.
16. Pease RJ, Milne RW, Jessup WK, Law A, Provost P, Fruchart JC, et al. Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem. 1990; 265: 553-68.
17. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol Ed John E Coligan Al. 2001; Appendix 3:Appendix 3B.
18. Brace RJ, Sorrenson B, Sviridov D, McCormick SPA. A gel-based method for purification of apolipoprotein A-I from small volumes of plasma. J Lipid Res. 2010; 51: 3370-6. doi: 10.1194/jlr.D008300
19. Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res. 2003; 44: 296-302.
20. Boisvert WA, Lee C-H, Laffitte BA, Barak Y, Joseph SB, Liao D, et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis. Mol Cell. 2001; 7: 161-71.
21. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994; 35: 779-92.
22. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1992; 10: 1386-9.
23. Bell KE, Di Sebastiano KM, Vance V, Hanning R, Mitchell A, Quadrilatero J, et al. A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory. Clin Nutr. 2014; 33: 550-7. doi: 10.1016/j.clnu.2013.08.001
24. Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011; 11: 1008-16.
25. Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem. 2013; 288: 18707-15. doi: 10.1074/jbc.R113.479808